Evaluation of the Benefits of Administering Immunosuppressive Drugs as Single Daily Doses Over the First Year After Liver Transplantation (EASY)

NCT06354179 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

162

Enrollment

OTHER

Sponsor class

Conditions

Liver Transplantation
Immunosuppression

Interventions

DRUG: XR-tacrolimus QD + MMF BID then MMF QD
DRUG: XR-tacrolimus QD + MMF BID
DRUG: LCP-tacrolimus QD + MMF QD then MMF QD
DRUG: LCP-tacrolimus QD + MMF BID

Sponsor

University Hospital, Limoges